https://orcid.org/0000-0003-2845-0938
References
- Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung cancer (Amsterdam, Netherlands). 54(1), 1–9 (2006).
- Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 65(Suppl. 2), ii32–ii40 (2010).
- Lorenzo MJ, Modesto M, Pérez J et al. Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: a prospective study. Palliat. Med. 28(4), 326–334 (2014).
- Clive AO, Kahan BC, Hooper CE et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 69(12), 1098–1104 (2014).
- Steyerberg EW, Moons KG, van der Windt DA et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLOS Med. 10(2), e1001381 (2013).
- Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. John Wiley & Sons, NJ, USA (2013).
- Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ 338, b605 (2009).
- Jang RW, Caraiscos VB, Swami N et al. Simple prognostic model for patients with advanced cancer based on performance status. J. Oncol. Pract. 10(5), e335–341 (2014).
- Kao SC, Pavlakis N, Harvie R et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin. Cancer Res. 16(23), 5805–5813 (2010).
- Anevlavis S, Kouliatsis G, Sotiriou I et al. Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration 87(4), 311–316 (2014).
- Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363(8), 733–742 (2010).
- Martínez-Moragón E, Aparicio J, Sanchis J, Menéndez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 65(2), 108–113 (1998).
- Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann. Thoraci. Surg. 84(5), 1656–1661 (2007).
- Wahidi MM, Reddy C, Yarmus L et al. Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions. The ASAP Trial. Am. J. Respir. Crit. Care Med. 195(8), 1050–1057 (2017).
- Davies HE, Mishra EK, Kahan BC et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 307(22), 2383–2389 (2012).
- Thomas R, Fysh ETH, Smith NA et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA 318(19), 1903–1912 (2017).
- Loureiro H, Becker T, Bauer-Mehren A, Ahmidi N, Weberpals J. Artificial Intelligence for Prognostic Scores in Oncology: a Benchmarking Study. Front. Artif. Intel. 4, 625573 (2021).